It’s been nearly a year since the EveryLife Foundation for Rare Diseases released its expansive report finding the total economic burden of rare disorders in the U.S. to be nearly $1 trillion.
The inhalation of tiny plastic particles called polystyrene microplastics — an emerging pollutant that affects both terrestrial and aquatic ecosystems — was associated with the development of pulmonary fibrosis (PF) in healthy mice, a study shows. Notably, these microplastics were found to promote oxidative stress and damage to lung cells,…
Boehringer Ingelheim Canada has finished negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) — a partnership between the country’s provincial, territorial and federal governments — for Ofev (nintedanib), the company’s approved oral medication for progressive fibrosing interstitial lung diseases (PF-ILD). The pCPA conducts negotiations with drug manufacturers for treatments…
C21 (VP01), Vicore Pharma’s investigational oral therapy, safely and effectively improves or stabilizes lung function in previously untreated adults with idiopathic pulmonary fibrosis (IPF), according to interim data from the open-label Phase 2 AIR trial. “Based on the mechanism of action of C21, which has both vascular and…
An analysis of gene activity profiles in lung tissue has identified important drivers of idiopathic pulmonary fibrosis (IPF). The genes discovered in this integrative analysis may predict disease outcomes and be used as potential therapeutic targets for new anti-fibrotic treatments, according to researchers. The study, “Integrative…
Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…
A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…
Endeavor BioMedicines has raised $101 million to advance its pipeline programs, including taladegib (ENV-101), an investigational oral treatment for idiopathic pulmonary fibrosis (IPF) now in a clinical trial, and for cancer linked to mutations in the PTCH1 gene. The funding was the result of a series B…
The more monocyte immune cells that circulate in a person’s bloodstream, the greater the odds that lung abnormalities, such as those linked to pulmonary fibrosis, will show up on a CT imaging scan, a study found. Researchers also observed that a higher monocyte count increased the odds of lung…
Algernon Pharmaceuticals hit the full enrollment of 20 patients with idiopathic pulmonary fibrosis (IPF) in its Phase 2 study of NP-120 (ifenprodil) for persistent, hard-to-treat cough, a common symptom of the disease. Early interim data from the study (NCT04318704), underway in Australia and New Zealand, showed…
Get regular updates to your inbox.
